Table 3.

Treatment outcomes, by treatment group and cirrhosis status

	Telaprevir			Boceprevir
	Total (n=211)	Non- cirrhotic (n=163)	Cirrhotic (n=48)	Total (n=141)	Non- cirrhotic (n=116)	Cirrhotic (n=25)
On treatment failure
Virologic breakthrough	2 (9%)	1 (1%)	1 (2%)	0	0	0
Futility	26 (12%)	13 (8%)	13 (27%)	16 (11%)	13 (11%)	3 (12%)
On treatment responses
Week 4 (TVR) or week 8 (BOC) response +	87 (41%)	76 (47%)	11 (23%)	76 (54%)	67 (58%)	9 (36%)
Week 12 response	160 (76%)	131 (80%)	29 (60%)	90 (64%)	79 (68%)	11 (44%)
End of treatment response¥, n (%)	136 (64%)	116 (71%)	20 (42%)	95 (67%)	79 (68%)	16 (64%)
Relapse†, n (%)	9 (4%)	6 (4%)	3 (6%)	17 (10%)	13 (11%)	4 (16%)
Sustained virologic response‡, n (%)	118 (56%)	109 (67%)	15 (31%)	75 (53%)	63 (54%)	12 (48%)

⁺Response was defined as undetectable HCV RNA level at a sensitivity of <15 IU/ml

^¥End of treatment response was defined as undetectable HCV RNA level at the end of the treatment period. 4 patients (3 TVR, 1 BOC) were lost to follow-up during treatment

^†Relapse was defined as detectable HCV RNA level after treatment completion in a subject with an undetectable HCV RNA level at end of treatment

^‡Sustained virologic response (SVR) was defined as undetectable HCV RNA level at least 12 weeks after treatment discontinuation. 4 TVR-treated and 3 BOC-treated patients stopped treatment prematurely but achieved SVR. 19 patients with end of treatment response were lost to follow-up after treatment ended (13 TVR, 6 BOC)